Cdex (CDEX) 10-Q 15 Jun 15 2015 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Apr. 30, 2015	Jun. 12, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	CDEX INC
Entity Central Index Key	1173738
Trading Symbol	CDEX
Current Fiscal Year End Date	-21
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	30-Apr-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		81,452,520
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Apr. 30, 2015	Oct. 31, 2014
Current assets
Cash	$49,273	$90,915
Accounts receivable	5,535	6,935
Inventory - net	250,126	250,751
Prepaid expenses and deposits	2,938	19,078
Total current assets	307,872	367,679
Property and equipment, net	18,438	28,709
Patents, net	44,863	46,913
Other assets	1,399	1,399
Total assets	372,572	444,700
Current liabilities
Accounts payable and accrued expenses	46,087	72,885
Deferred revenue - current	61,000	67,000
Line of credit payable	499,401	135,288
Total current liabilities	606,488	275,173
Total liabilities	606,488	275,173
Commitments and Contingencies
Stockholders' equity
Class A common stock - $.005 par value per share, 300,000,000 shares authorized and 69,452,958 outstanding at April 30, 2015 and at October 31, 2014	347,263	347,263
Additional paid in capital	35,619,772	35,619,772
Accumulated (deficit)	-36,200,982	-35,797,539
Total stockholders' equity (deficit)	-233,916	169,527
Total liabilities and stockholders' equity	372,572	444,700
Preferred stock - undesignated - $.005 par value per share, 350,000 shares authorized and none outstanding
Stockholders' equity
Preferred stock
Preferred stock - series A - $.005 par value per share, 150,000 shares authorized and 6,250 outstanding at April 30, 2015 and at October 31, 2014
Stockholders' equity
Preferred stock	$31	$31

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Apr. 30, 2015	Oct. 31, 2014
Stockholders' equity
Preferred stock, par value per share (in Dollars per Share)	$0.01	$0.01
Common stock, par value per share (in Dollars per Share)	$0.01	$0.01
Common stock, shares authorized (in Shares)	300,000,000	300,000,000
Common stock, shares outstanding (in Shares)	69,452,958	69,452,958
Preferred stock - undesignated [Member]
Stockholders' equity
Preferred stock, shares authorized (in Shares)	350,000	350,000
Preferred stock, shares outstanding (in Shares)	0	0
Preferred stock - series A [Member]
Stockholders' equity
Preferred stock, shares authorized (in Shares)	150,000	150,000
Preferred stock, shares outstanding (in Shares)	6,250	6,250

STATEMENTS_OF_OPERATIONS_unaud

STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended		6 Months Ended
	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
STATEMENTS OF OPERATIONS [Abstract]
Revenue	$36,762	$50,277	$58,884	$126,284
Cost of revenue	9,532	6,239	16,252	25,904
Gross profit	27,230	44,038	42,632	100,380
Operating Expenses
Selling, general and administrative	139,119	152,769	284,114	274,796
Research and development	39,971	34,596	84,686	91,151
Total operating expenses	179,090	187,365	368,800	365,947
Loss from operations	-151,860	-143,327	-326,168	-265,567
Other income
Interest expense	-47,434		-87,386
Other income	7,931		10,111	6,805
Total other income	-39,503		-77,275	6,805
Net loss	($191,363)	($143,327)	($403,443)	($258,762)
Basic net loss per common share (in Dollars per Share):	($0.01)	($0.01)	($0.01)	($0.01)
Basic weighted average common shares outstanding (in Shares)	69,452,958	54,344,042	69,452,958	53,645,503

STATEMENTS_OF_CASH_FLOWS_unaud

STATEMENTS OF CASH FLOWS (unaudited) (USD $)	6 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Cash Flows from Operating Activities
Net loss	($403,443)	($258,762)
Adjustments to reconcile net loss to cash used by operating activities
Depreciation and amortization	8,293	11,491
Non-cash amortization of bonus interest on notes payable	44,640
Non-cash amortization of warrants issued on notes payable	24,424
Share-based compensation		8,780
Interest expense	18,322
(Gain) loss recognized on disposal of equipment	-10,111
Changes in operating assets and liabilities
Accounts receivable	1,400	7,348
Inventory	625	8,282
Deferred costs and other assets	2,000	2,607
Current liabilities	-32,798	109,382
Net cash used by operating activities	-346,648	-110,872
Cash Flows from Investing Activities
Proceeds on sale of equipment	14,139
Purchase of equipment		-10,212
Net cash provided (used) by investing activities	14,139	-10,212
Cash Flows from Financing Activities
Proceeds received under line of credit	305,000
Proceeds from warrant exchange offer		140,000
Repayment under line of credit	-14,133
Net cash provided by financing activities	290,867	140,000
Net decrease in cash	-41,642	18,916
Cash, beginning of the period	90,915	98,967
Cash, end of the period	49,273	117,883
Supplemental Cash Flow Information
Cash payments for interest expense	$14,133

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Apr. 30, 2015
Basis of Presentation [Abstract]
Basis of Presentation	1. Basis of Presentation
	The accompanying interim unaudited condensed financial statements include the accounts of CDEX Inc. as of April 30, 2015.  In the opinion of management, all adjustments (which include normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented have been made. The results for the three-month and six-month periods ended April 30, 2015 may not be indicative of the results for the entire year. The interim unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements contained in our Annual Report on Form 10-K. Our lack of earnings history and continued future losses could adversely affect our financial position and if we are unable to generate funds or obtain funds on acceptable terms, we may not be able to continue operations.
	The accompanying unaudited financial statements are presented pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading.
	Recent Developments
	We have experienced net losses since our inception and, as of April 30, 2015, had an accumulated deficit of approximately $36 million.  We do not expect to have positive cash flow from operations until we have deployed a sufficient number of our ValiMedTM G4 drug validation systems.  As of April 30, 2015, we had approximately $49,000 in cash which was provided primarily through proceeds from our Lines of Credit.
	Use of Estimates
	The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management bases its assumptions on historical experiences and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. In addition, management considers the basis and methodology used in developing and selecting these estimates, the trends in and amounts of these estimates, specific matters affecting the amount of and changes in these estimates, and any other relevant matters related to these estimates, including significant issues concerning accounting principles and financial statement presentation. Such estimates and assumptions could change in the future as more information becomes known which could impact the amounts reported and disclosed herein. Significant estimates include revenue recognition, the valuation of inventory and stock-based compensation expense.
	Recent Accounting Pronouncements
	The Company has reviewed, and continues to review, issued accounting pronouncements with the intent of adopting any that are applicable to it. The Company does not expect any recent pronouncements to have an impact on its results of operations or financial position.

Inventory_Net

Inventory - Net	6 Months Ended
	Apr. 30, 2015
Inventory - Net [Abstract]
Inventory - Net	2.	Inventory - Net
	Our inventories consisted of the following:
			30-Apr-15			31-Oct-14
	Raw materials		$	228,311		$	223,464
	Finished goods			47,651			52,301
	Subtotal			275,962			275,765
	Obsolescence reserve			(25,836	)		(25,014	)
	Total inventory		$	250,126		$	250,751

Property_and_equipment_net

Property and equipment, net	6 Months Ended
	Apr. 30, 2015
Property and equipment, net [Abstract]
Property and equipment, net	3	Property and equipment, net
	Our property and equipment consisted of the following:
			30-Apr-15			31-Oct-14
	Furniture, fixtures and leasehold improvements		$	2,931		$	2,931
	Equipment			502,244			605,007
	Leased equipment			70,654			70,654
	Total			575,829			678,592
	Less accumulated depreciation			(557,391	)		(649,883	)
	Net property and equipment		$	18,438		$	28,709

Patents_net

Patents, net	6 Months Ended
	Apr. 30, 2015
Patents, net [Abstract]
Patents, net	4	Patents, net
	Our patents consisted of the following:
			30-Apr-15			31-Oct-14
	Patents		$	100,000		$	100,000
	Less accumulated amortization			(55,137	)		(53,087	)
	Net patents		$	44,863		$	46,913

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	6 Months Ended
	Apr. 30, 2015
Accounts Payable and Accrued Expenses [Abstract]
Accounts Payable and Accrued Expenses	5	Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consisted of the following:
			30-Apr-15		31-Oct-14
	Legal fees		$	-	$	61,571
	Accrued compensation			10,314		3,430
	Accounts payable			33,398		5,509
	Accrued payable to a distributor			2,375		2,375
			$	46,087	$	72,885

Lines_of_Credit

Lines of Credit	6 Months Ended
	Apr. 30, 2015
Lines of Credit [Abstract]
Lines of Credit	6.	Lines of Credit
	Effective October 16, 2014, CDEX Inc. (the “Company”) entered into a Line of Credit Agreement with each of two lenders, one of whom is our CEO, Jeffrey K. Brumfield, and the other of which is a significant shareholder, PEMCO LLC.  The Line of Credit Agreements provide for the lenders to make available to the Company an aggregate amount of up to $430,000 in funding, upon which the Company may draw funds as needed at any time from the effective date until the maturity date which has been extended to June 30, 2015. The Lines of Credit are secured by all assets of the Company. Pursuant to each Line of Credit Agreement, the Company has issued each lender a Revolving Note (collectively, the “Notes”) evidencing the net amount drawn by the Company during the term of the Line of Credit Agreement. The Notes bear interest at a rate of 12% per annum. Interest on the balance of the Notes accrues and is payable on the first day of each month beginning on November 1, 2014. On the maturity date, the Company must pay to the lenders an amount equal to 110% of the principal due on the Notes plus any accrued and unpaid interest as of that date. The Company may prepay any principal balance on the Notes, but it must still pay 110% of such principal amount when paid. As additional incentive for the lenders to enter into the Line of Credit Agreements and make available to the Company funds thereunder, the Company has issued to the lenders Warrants to purchase up to 2,150,000 shares of the Company’s Class A common stock in the aggregate. The Warrants are exercisable for a period of five years at an exercise price of $0.25 per share. The following reconciles notes payable as of April 30, 2015 and October 31, 2014:
			30-Apr-15			31-Oct-14
	Line of credit - PEMCO LLC - 12% interest payable monthly - matures			350,000			105,173
	June 30, 2015
	Line of credit - Jeffrey K Brumfield - 12% interest payable monthly - matures			100,000			40,039
	June 30, 2015
	Recognition of 10% bonus interest on lines of credit draws			45,000			14,500
	Recognition of warrant value on lines of credit			(25,075	)		(25,075	)
	Accrued Interest			4,401			-
	Amortization of warrant value on lines of credit			25,075			651
	Total lines of credit			499,401			135,288

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Apr. 30, 2015
Share-Based Compensation [Abstract]
Share-Based Compensation	7.	Share-Based Compensation
	For the six month periods ended April 30, 2015 there was no share-based compensation expense.  For the three and six months ended April 30, 2014, share-based compensation expense was approximately $9,000, primarily attributable to restricted stock grants issued to our independent Directors under the CDEX Inc. Board Compensation Plan.
	During the six month periods ended April 30, 2015 there was no option or stock grant activity.  During the six months ended April 30, 2014, 15,000 options were forfeited and approximately 276,000 shares of restricted stock were issued.
	We determine the fair value of share-based awards at their grant date, using a Black-Scholes Option Pricing Model.  No options were granted for the six month periods ended April 30, 2015 and April 30, 2014.
	As of April 30, 2015, there were no unrecognized compensation costs related to unvested restricted stock grants.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Apr. 30, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	8.	Stockholders' Equity
	During the three month periods ended April 30, 2015 and April 30, 2014, there was no stock activity.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Apr. 30, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	9.	Commitments and Contingencies
	Litigation
	We may from time to time be involved in legal proceedings arising from the normal course of business. As of the date of this report, we have not received notice of any other legal proceedings and the Company is not aware of any pending claims or assessments which may have a material adverse impact on the Company’s financial position or results of operations.

Subsequent_Events

Subsequent Events	6 Months Ended
	Apr. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events
	The Company’s management has evaluated subsequent events occurring after April 30, 2015, the date of our most recent balance sheet, through the date our financial statements were issued.
	Effective May 28, 2015, CDEX Inc. (the “Company”) entered into a Consulting Advisory Services Agreement (the “Agreement”) with Osprey Capital Advisors, LLC, a Florida limited liability company (the “Consultant”).  The Agreement calls for the Consultant to provide advisory and consulting services to the Company, including introduction to, and establishing relationships with, individuals and entities for possible investment in the Company, guidance on markets, product distribution, employment, board development and related matters, business plan development, review of the Company’s long- and short-term growth objectives, investor relations and public relations services and the Company’s approach to its business and financial strategy and efforts taken by the Company to date to develop investor interest.
	As consideration for such services, the Company has agreed to issue to the Consultant an aggregate of 12 million shares of its Class A common stock, 7.5 million of such shares issuable upon signing of the Agreement.  The Agreement has a term of 240 days.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Apr. 30, 2015
Basis of Presentation [Abstract]
Basis of Presentation, Policy	1. Basis of Presentation
	The accompanying interim unaudited condensed financial statements include the accounts of CDEX Inc. as of April 30, 2015.  In the opinion of management, all adjustments (which include normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented have been made. The results for the three-month and six-month periods ended April 30, 2015 may not be indicative of the results for the entire year. The interim unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements contained in our Annual Report on Form 10-K. Our lack of earnings history and continued future losses could adversely affect our financial position and if we are unable to generate funds or obtain funds on acceptable terms, we may not be able to continue operations.
	The accompanying unaudited financial statements are presented pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to those rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading.
Recent Developments, Policy	Recent Developments
	We have experienced net losses since our inception and, as of April 30, 2015, had an accumulated deficit of approximately $36 million.  We do not expect to have positive cash flow from operations until we have deployed a sufficient number of our ValiMedTM G4 drug validation systems.  As of April 30, 2015, we had approximately $49,000 in cash which was provided primarily through proceeds from our Lines of Credit.
Use of Estimates, Policy	Use of Estimates
	The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Management bases its assumptions on historical experiences and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. In addition, management considers the basis and methodology used in developing and selecting these estimates, the trends in and amounts of these estimates, specific matters affecting the amount of and changes in these estimates, and any other relevant matters related to these estimates, including significant issues concerning accounting principles and financial statement presentation. Such estimates and assumptions could change in the future as more information becomes known which could impact the amounts reported and disclosed herein. Significant estimates include revenue recognition, the valuation of inventory and stock-based compensation expense.
Recent Accounting Pronouncements, Policy	Recent Accounting Pronouncements
	The Company has reviewed, and continues to review, issued accounting pronouncements with the intent of adopting any that are applicable to it. The Company does not expect any recent pronouncements to have an impact on its results of operations or financial position.

Inventory_Net_Tables

Inventory - Net (Tables)	6 Months Ended
	Apr. 30, 2015
Inventory - Net [Abstract]
Schedule of Inventory	Our inventories consisted of the following:
		30-Apr-15			31-Oct-14
	Raw materials	$	228,311		$	223,464
	Finished goods		47,651			52,301
	Subtotal		275,962			275,765
	Obsolescence reserve		(25,836	)		(25,014	)
	Total inventory	$	250,126		$	250,751

Property_and_equipment_net_Tab

Property and equipment, net (Tables)	6 Months Ended
	Apr. 30, 2015
Property and equipment, net [Abstract]
Schedule of Property and Equipment	Our property and equipment consisted of the following:
		30-Apr-15			31-Oct-14
	Furniture, fixtures and leasehold improvements	$	2,931		$	2,931
	Equipment		502,244			605,007
	Leased equipment		70,654			70,654
	Total		575,829			678,592
	Less accumulated depreciation		(557,391	)		(649,883	)
	Net property and equipment	$	18,438		$	28,709

Patents_net_Tables

Patents, net (Tables)	6 Months Ended
	Apr. 30, 2015
Patents, net [Abstract]
Schedule of Patents	Our patents consisted of the following:
		30-Apr-15			31-Oct-14
	Patents	$	100,000		$	100,000
	Less accumulated amortization		(55,137	)		(53,087	)
	Net patents	$	44,863		$	46,913

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Apr. 30, 2015
Accounts Payable and Accrued Expenses [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following:
		30-Apr-15		31-Oct-14
	Legal fees	$	-	$	61,571
	Accrued compensation		10,314		3,430
	Accounts payable		33,398		5,509
	Accrued payable to a distributor		2,375		2,375
		$	46,087	$	72,885

Lines_of_Credit_Tables

Lines of Credit (Tables)	6 Months Ended
	Apr. 30, 2015
Lines of Credit [Abstract]
Lines of Credit	The following reconciles notes payable as of April 30, 2015 and October 31, 2014:
		30-Apr-15			31-Oct-14
	Line of credit - PEMCO LLC - 12% interest payable monthly - matures		350,000			105,173
	June 30, 2015
	Line of credit - Jeffrey K Brumfield - 12% interest payable monthly - matures		100,000			40,039
	June 30, 2015
	Recognition of 10% bonus interest on lines of credit draws		45,000			14,500
	Recognition of warrant value on lines of credit		(25,075	)		(25,075	)
	Accrued Interest		4,401			-
	Amortization of warrant value on lines of credit		25,075			651
	Total lines of credit		499,401			135,288

Basis_of_Presentation_Narrativ

Basis of Presentation (Narrative) (Details) (USD $)	Apr. 30, 2015	Oct. 31, 2014	Apr. 30, 2014	Oct. 31, 2013
Basis of Presentation [Abstract]
Accumulated deficit	$36,200,982	$35,797,539
Cash	$49,273	$90,915	$117,883	$98,967

Inventory_Net_Schedule_of_Inve

Inventory - Net (Schedule of Inventory) (Details) (USD $)	Apr. 30, 2015	Oct. 31, 2014
Inventory - Net [Abstract]
Raw materials	$228,311	$223,464
Finished goods	47,651	52,301
Subtotal	275,962	275,765
Obsolescence reserve	-25,836	-25,014
Total inventory	$250,126	$250,751

Property_and_equipment_net_Sch

Property and equipment, net (Schedule of Property Plant and Equipment) (Details) (USD $)	Apr. 30, 2015	Oct. 31, 2014
Property and equipment, net [Abstract]
Furniture, fixtures and leasehold improvements	$2,931	$2,931
Equipment	502,244	605,007
Leased equipment	70,654	70,654
Total	575,829	678,592
Less accumulated depreciation	-557,391	-649,883
Net property and equipment	$18,438	$28,709

Patents_net_Schedule_of_Finite

Patents, net (Schedule of Finite Lived Intangible Assets) (Details) (USD $)	Apr. 30, 2015	Oct. 31, 2014
Patents, net [Abstract]
Patents	$100,000	$100,000
Less accumulated amortization	-55,137	-53,087
Net patents	$44,863	$46,913

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Schedule of Accounts Payable and Accrued Liabilities) (Details) (USD $)	Apr. 30, 2015	Oct. 31, 2014
Accounts Payable and Accrued Expenses [Abstract]
Legal fees		$61,571
Accrued compensation	10,314	3,430
Accounts payable	33,398	5,509
Accrued payable to a distributor	2,375	2,375
Total	$46,087	$72,885

Lines_of_Credit_Narrative_Deta

Lines of Credit (Narrative) (Details) (USD $)	6 Months Ended
	Apr. 30, 2015
Short-Term Debt [Line Items]
Number of related party lenders	$2
Line of credit maximum borrowing capacity	$430,000
Line of credit facility initiation date	16-Oct-14
Line of credit maturity date	30-Jun-15
Line of credit stated interest rate	2.00%
Line of credit date repayment is due	1-Nov-14
Line of credit, percent of principal due on maturity	110.00%
Line of credit consideration, shares issuable with warrants issued (in Shares)	2,150,000
Line of credit, warrant consideration, warrant term	5 years
Line of credit, warrant consideration, warrant exercise price (in Dollars per Share)	$0.25

Lines_of_Credit_Schedule_Recon

Lines of Credit (Schedule Reconciling Notes Payable Activity During the the Current ad Prior Year) (Details) (USD $)	Apr. 30, 2015	Oct. 31, 2014
Short-Term Debt [Line Items]
Line of credit payable	$499,401	$135,288
Line of credit - PEMCO LLC (Related Party - Significant Shareholder) - 12% interest payable monthly - matures March 31, 2015
Short-Term Debt [Line Items]
Line of credit payable	350,000	105,173
Line of credit - Jeffrey K Brumfield (Related Party - CEO) - 12% interest payable monthly - matures March 31, 2015
Short-Term Debt [Line Items]
Line of credit payable	100,000	40,039
Recognition of 10% bonus interest on lines of credit draws [Member]
Short-Term Debt [Line Items]
Line of credit payable	45,000	14,500
Recognition of warrant value on lines of credit [Member]
Short-Term Debt [Line Items]
Line of credit payable	-25,075	-25,075
Accrued Interest [Member]
Short-Term Debt [Line Items]
Line of credit payable	4,401
Amortization of warrant value on lines of credit [Member]
Short-Term Debt [Line Items]
Line of credit payable	$25,075	$651

ShareBased_Compensation_Narrat

Share-Based Compensation (Narrative) (Details) (USD $)	3 Months Ended	6 Months Ended
	Apr. 30, 2014	Apr. 30, 2015	Apr. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$8,780		$8,780
Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of options forfeited (in Shares)			15,000
Options granted in period (in Shares)		0	0
Stock grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-option instruments granted in period (in Shares)		0	0
Restricted stock grants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-option instruments granted in period (in Shares)			276,000
Unrecognized compensation costs related to unvested restricted stock grants		$0

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details)	3 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Stockholders' Equity [Abstract]
Common stock issued (in Shares)	0	0

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details)	6 Months Ended
	Apr. 30, 2015	Jun. 12, 2015
Subsequent Events [Abstract]
Subsequent event, date of Consulting Advisory Services Agreement entered into (in Date)	28-May-15
Subsequent event, total shares issuable under Consulting Services Agreement		12,000,000
Subsequent event, shares issuable on execution of Consulting Services Advisory Agreement (in Shares)		7,500,000
Subsequent event, term of Consulting Services Advisory Agreement (n Duration)	240 days